


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of _____

Application Number

07/456 697

Filed

12-22-89

Art Unit

Examiner

Paper No. 47Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 5284931, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Signature

3-24-03
Date

HENRY MOORE
Typed or printed name

FOR PTO USE ONLY

Approved by: PSY

(initials)

Unit: _____



US005284931A

United States Patent [19][11] **Patent Number:** 5,284,931

Springer et al.

[45] **Date of Patent:** Feb. 8, 1994[54] **INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS**[75] **Inventors:** Timothy A. Springer, Newton, Mass.; Robert Rothlein; Steven D. Marlin, both of Danbury, Conn.; Michael L. Dustin, University City, Mo.[73] **Assignee:** Dana Farber Cancer Institute, Boston, Mass.[21] **Appl. No.:** 515,478[22] **Filed:** Apr. 27, 1990**Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 436,647, Dec. 22, 1989, which is a continuation-in-part of Ser. No. 43,963, May 4, 1987, which is a continuation-in-part of Ser. No. 115,798, Nov. 2, 1987, which is a continuation-in-part of Ser. No. 155,943, Feb. 16, 1988, which is a continuation-in-part of Ser. No. 189,815, May 3, 1988, which is a continuation-in-part of Ser. No. 230,446, Sep. 28, 1988, which is a continuation-in-part of Ser. No. 324,481, Mar. 16, 1989, which is a continuation-in-part of Ser. No. 373,882, Jun. 30, 1989, which is a continuation-in-part of Ser. No. 436,647, Dec. 22, 1989.

[51] **Int. Cl.** A61K 39/395[52] **U.S. Cl.** 424/85.8; 530/388.22; 530/395; 530/808; 530/868; 514/8[58] **Field of Search** 424/85.8, 85.91; 530/387, 389, 808, 388.22[56] **References Cited**
PUBLICATIONS

Cunningham C, et al., *TIBTECH* 10, Apr., 1992. "Antibody engineering—how to be human."
Daniel, J., et al., *Curr. Opin. Immunol.* 3:740-747 (1991), "Use of Monoclonal antibodies in human transplantation."
Flavin, T., et al., *Transpl. Proc.* 23(1):533-534 (Feb. 1991) "Monoclonal antibodies against intercellular adhesion molecule 1 prolong carioige allograft survival in CY momolgus monkeys."
Gibbs, W. W., *Scientific American* (Jul. 1993), "Try, try again," pp. 101-103.

Hans, W. J., et al. *Tibtech* 11 (Feb. 1993), pp. 42-44. "Therapeutic antibodies—the coming of age."Haug, C. E., et al., *Transplantation* 55:766-773, (Apr. 1993), "A Phase I trial of immunosuppression with anti-, cam-12 (CD54) m Ab in renal allograft recipients."Ortho Multicenter Transplant Study Group, *New Engl. J. Med.* 313:337-341 (Aug. 8, 1985).

Physician's Desk Reference (1993), pp. 1702-1703. "Orthoclone OKT3".

Marlin, S. D. et al. 1987. *Cell* 51: 813-819. "Purified Intercellular Adhesion Molecule-1 . . ."Rothlein, R. et al. 1986. *J. Immunol.* 137:1270-1274. "A Human Intercellular Adhesion Molecule (ICAM-1) . . ."Dustin, M. L. et al. 1986. *J. Immunol.* 137(1):245 "Induction by IL1 and Interferon- γ . . ."Cosimi et al., *J. Immunol.* 144(12):4604-4612 (1990).Flavin et al., *Transplant. Proc.* 23(1):553-534 (1991).Tolkoff-Rubin et al., *J. Amer. Soc. Nephrology* 2(3):820 No. 2P (1991).Kavanaugh et al., *56th Meeting of Amer. College of Rheumatology*, Oct. 13-15, Atlanta, Ga. (1992).Boyd et al., *Proc. Natl. Acad. Sci. USA* 85:3095-3099 (1988).

(List continued on next page.)

Primary Examiner—Christine M. Nucker
Assistant Examiner—Thomas Cunningham
Attorney, Agent, or Firm—Sterne, Kessler, Goldstein & Fox

[57] **ABSTRACT**

Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunosuppressive agents.

11 Claims, 23 Drawing Sheets

To: Henry
#905271